ivermectin for COVID-19: a live meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	RCT OBS RCT + OBS	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID 19 hospitalized meta-analysis
Elgazzar - treatment, 2020		RCT	ivermectin	hydroxychloroquine	COVID 19 hospitalized	high	200/200	suggested	suggested 93 % decrease in deaths but with a low degree of certainty due to high risk of bias
Gonzalez_IVER, 2020 NCT04391127		RCT	ivermectin	placebo	COVID 19 hospitalized	some concern	36/37	inconclusive
ICON, 2020		OBS	ivermectin	standard of care	COVID 19 hospitalized	NA	173/107	suggested	suggested 53 % decrease in deaths (PE)
Khan, 2020		OBS	ivermectin	standard of care	COVID 19 hospitalized, COVID-19 mild to moderate	NA	115/133	suggested	suggested 88 % decrease in deaths suggested 7.3-fold increase in clinical improvement suggested 88 % decrease in ventilation
COVID-19 mild to moderate meta-analysis
Babalola, 2021		RCT	ivermectin	lopinavir/ritonavir	COVID-19 mild to moderate	high	21/20	no results
Bukhari, 2021 NCT04392713		RCT	ivermectin	standard of care	COVID-19 mild to moderate	high	50/50	suggested	suggested 10.6-fold increase in viral clearance by day 7 but with a low degree of certainty due to high risk of bias
Kirti, 2021 CTRI/2020/08/027225		RCT	ivermectin	placebo	COVID-19 mild to moderate	some concern	57/58	inconclusive	inconclusive 20 % decrease in viral clearance by day 7 (PE) with a moderate degree of certainty due to some concern in risk of bias
RIVET-COV (Mohan), 2021 CTRI/2020/06/026001		RCT	ivermectin	placebo	COVID-19 mild to moderate	high	100/52	inconclusive
Ahmed, 2020		RCT	ivermectin	placebo	COVID-19 mild to moderate	high	48/24	suggested	suggested 3.1-fold increase in viral clearance (time to event analysis only),viral clearance by day 14 (PE) but with a low degree of certainty due to high risk of bias Paradoxically comparison of day 7 and 14 virological clearance between ivermectin doxycycline group vs placebo was not statistically significant (HR 2.3[0.6-9.0] and 1.7[0.8-4.0])
Chaccour, 2020 NCT04390022		RCT	ivermectin	placebo	COVID 19 outpatients, COVID-19 mild to moderate	low	12/12	inconclusive	inconclusive 8 % decrease in viral clearance ,viral clearance by day 7 (PE) with a high degree of certainty due to low risk of bias
Chachar, 2020 NCT04739410		RCT	ivermectin	standard of care	COVID-19 mild to moderate	high	25/25	inconclusive	inconclusive 19 % increase in clinical improvement,clinical improvement (7-day) (PE) but with a low degree of certainty due to high risk of bias
Krolewiecki, A, 2020 NCT04381884		RCT	ivermectin	standard of care	COVID-19 mild to moderate	some concern	30/15	inconclusive	Viral load reduction between baseline and day-5 was also similar between groups
Glorial F, 2020 NCT04343092		OBS	ivermectin	standard of care	COVID-19 mild to moderate	NA	6/71	inconclusive	inconclusive 10 % decrease in clinical improvement (PE)
Soto-Becerra, 2020		OBS	ivermectin	standard of care	COVID 19 hospitalized, COVID-19 mild to moderate	moderate	203/2630	safety concern	inconclusive 39 % increase in deaths,deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias statistically significant 58 % increase in death or transfer to ICU with a moderate degree of certainty due to some concern in risk of bias Our study reported no beneficial effects of hydroxychloroquine, ivermectin, azithromycin. The HCQ AZIT treatment seems to increase risk for all-cause death
Espitia-Hernandez, 2020		NRa	ivermectin	standard of care	COVID 19 outpatients, COVID-19 mild to moderate	NA	28/7	suggested	suggested 714.0-fold increase in viral clearance
Spoorthi, 2020		NRa	ivermectin	placebo	COVID 19 hospitalized, COVID-19 mild to moderate	NA	50/50	inconclusive
COVID-19 severe or critically meta-analysis
Galan, 2021 RBR-8h7q82		RCT	ivermectin	chloroquine and derivatives	COVID-19 severe or critically	some concern	53/115	suggested	inconclusive 6 % decrease in deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias suggested 86 % decrease in ventilation with a moderate degree of certainty due to some concern in risk of bias
Galan, 2021 RBR-8h7q82		RCT	ivermectin	hydroxychloroquine	COVID-19 severe or critically	some concern	53/115	suggested	inconclusive 6 % decrease in deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias suggested 86 % decrease in ventilation with a moderate degree of certainty due to some concern in risk of bias
Niaee (vs placebo), 2020 IRCT20200408046987N1		RCT	ivermectin	control	COVID-19 severe or critically	high	120/30	suggested	suggested 86 % decrease in deaths but with a low degree of certainty due to high risk of bias
Okumuş, 2020 NCT04646109		RCT	ivermectin	control	COVID-19 severe or critically	high	30/30	inconclusive
Camprubi, 2020		OBS	ivermectin	standard of care	COVID-19 severe or critically	NA	13/13	inconclusive
COVID 19 outpatients meta-analysis
Lopez-Medina, 2021 NCT04405843		RCT	ivermectin	placebo	COVID 19 outpatients	some concern	200/200	inconclusive	inconclusive 7 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
Podder, 2020		RCT	ivermectin	standard of care	COVID 19 outpatients	high	32/30	inconclusive

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID 19 hospitalized meta-analysis

COVID-19 mild to moderate meta-analysis

COVID-19 severe or critically meta-analysis

COVID 19 outpatients meta-analysis